Wockhardt Ltd
Ticker: WOCKPHARMA
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
1355.20
Market Cap
22020.94
Debt/Equity
0.4340
ROE %
-1.130
PB
4.7286
Promoter %
49.087
Pledge %
7.678
1Y Rev Growth %
6.699
5Y Rev Growth %
0.641
NP Margin %
-1.529
NP Margin 5Y Avg %
-5.467
Trading Reference
1M Return %
-10.151
6M Return %
-3.359
1Y Return %
25.412
% Away 52W High
37.898
% Away 52W Low
34.698
Daily Volume
303086
Investment Verdict
Avoid
Score 34/100 · Position size: 0%
Fundamentals/valuations or risk flags are weak. Avoid for long-term investing.
Trading Verdict
Avoid
Score 8/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Wockhardt Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend if it breaks above recent resistance. Volume has been increasing, suggesting bullish sentiment. Therefore, there is a moderate probability of price appreciation in the medium term, with potential for a rally if momentum continues.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Aegis Logistics Ltd
Aegis Logistics Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
M
Manappuram Finance Ltd
Manappuram Finance Ltd shows potential for growth but is facing several challenges that could impact its performance.
View details
O
Ola Electric Mobility Ltd
Ola Electric Mobility Ltd shows potential in a growing sector but faces significant challenges in execution and profitability.
View details
N
Navin Fluorine International Ltd
Navin Fluorine International Ltd shows potential for growth in a favorable sector, but investors should be cautious of valuation and execution risks.
View details
T
Tata Chemicals Ltd
Tata Chemicals Ltd shows potential with a decent score, but investors should be cautious due to fluctuating profitability and valuation concerns.
View details
A
Aditya Birla Sun Life AMC Ltd
Aditya Birla Sun Life AMC Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investments.
View details
P
Piramal Enterprises Ltd
Piramal Enterprises has potential but faces challenges in growth consistency and market valuation.
View details
R
Ramco Cements Limited
Ramco Cements shows potential for growth but faces challenges in profitability and valuation metrics.
View details
F
Force Motors Ltd
Force Motors Ltd presents several risks with inconsistent growth and profitability, making it a risky investment at this time.
View details
H
HBL Engineering Ltd
HBL Engineering Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Pfizer Ltd
Pfizer Ltd shows decent potential with consistent growth, but faces valuation challenges and execution risks.
View details
D
Deepak Nitrite Ltd
Deepak Nitrite Ltd shows decent potential with consistent growth, but faces valuation concerns and execution risks.
View details
S
SKF India Ltd
SKF India Ltd shows decent potential with stable growth prospects, but faces challenges in profitability and valuation metrics.
View details
K
KEC International Ltd
KEC International Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
N
Nuvama Wealth Management Ltd
Nuvama Wealth Management Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
H
Himadri Speciality Chemical Ltd
Himadri Speciality Chemical Ltd shows potential in a growing sector, but faces challenges in execution and market competition.
View details
Business Overview
Wockhardt Ltd is a leading global pharmaceutical and biotechnology company based in India, dedicated to improving health outcomes through innovative products. Catering to diverse markets, including generics, biosimilars, and specialty pharmaceuticals, Wockhardt plays a crucial role in enhancing access to quality healthcare. With a strong emphasis on research and development, the company is committed to delivering effective treatments for various medical conditions. Wockhardt's focus on quality, compliance, and sustainability makes it a trusted partner in the healthcare industry.
- Global leader in pharmaceuticals and biotechnology
- Innovative solutions for diverse health needs
- Strong focus on research and development
- Commitment to quality and compliance
- Sustainable practices in healthcare delivery
Investment Thesis
Wockhardt Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth in digital services, and attractive valuation compared to peers. The company's strategic focus on innovation and expansion positions it well for future growth, making it a valuable addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment shows promising growth potential, aligning with market trends.
- Attractive valuation metrics compared to industry peers offer a favorable entry point.
- Robust product pipeline and R&D investments poised to drive long-term growth.
- Resilience in the pharmaceutical sector amidst economic fluctuations supports stability.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Expanding international markets
- Rising demand for generics
- Strategic partnerships with global firms
Risks ⚠️
- Regulatory challenges in India
- High debt levels
- Intense competition in pharmaceuticals
- Volatility in raw material prices
Peer Perspective
Wockhardt Ltd trades at a discount to peers like Cipla and Sun Pharma, with a focus on improving margin stability and accelerating growth being crucial for potential rerating in the competitive pharma landscape.
Future Outlook
Wockhardt Ltd has strong potential for growth driven by its innovative pipeline and expanding markets; however, successful execution and stringent cost control will be crucial to fully realize these opportunities.
📊 Stock Investment Checklist (100 Points)
Wockhardt Ltd • Updated: 2025-09-18 08:50:08
-
8BusinessHighPharmaceutical sector is essential but faces regulatory challenges.
-
10GrowthHighInconsistent revenue growth due to market competition.
-
10ProfitabilityHighModerate ROE and ROCE, but cash flow issues persist.
-
9ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
6BalanceGoodHigh debt levels relative to equity raise concerns.
-
7GovernanceHighPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified, execution risks are high.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Risky
Wockhardt Ltd presents several risks, particularly in growth consistency and balance sheet strength, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100